The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies

被引:58
作者
Kalk, N. J. [1 ]
Nutt, D. J. [2 ]
Lingford-Hughes, A. R. [2 ]
机构
[1] Univ Bristol, Dept Psychopharmacol, Bristol BS1 3NY, Avon, England
[2] Univ London Imperial Coll Sci Technol & Med, Neuropsychopharmacol Unit, London, England
关键词
Anxiety disorders; noradrenaline; GROWTH-HORMONE RESPONSE; POSTTRAUMATIC-STRESS-DISORDER; OBSESSIVE-COMPULSIVE DISORDER; ALPHA(2)-ADRENERGIC RECEPTOR SENSITIVITY; 35-PERCENT CARBON-DIOXIDE; PANIC DISORDER; CEREBROSPINAL-FLUID; DOUBLE-BLIND; PLASMA-CATECHOLAMINES; PLATELET ALPHA(2)-ADRENORECEPTORS;
D O I
10.1177/0269881110367448
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The nature of the noradrenergic dysregulation in clinical anxiety disorders remains unclear. In panic disorder, the predominant view has been that central noradrenergic neuronal networks and/or the sympathetic nervous system was normal in patients at rest, but hyper-reactive to specific stimuli, for example carbon dioxide. These ideas have been extended to other anxiety disorders, which share with panic disorder characteristic subjective anxiety and physiological symptoms of excess sympathetic activity. For example, Generalized Anxiety Disorder is characterized by chronic free-floating anxiety, muscle tension, palpitation and insomnia. It has been proposed that there is chronic central hypersecretion of noradrenaline in Generalized Anxiety Disorder, with consequent hyporesponsiveness of central post-synaptic receptors. With regards to other disorders, it has been suggested that there is noradrenergic involvement or derangement, but a more specific hypothesis has not been enunciated. This paper reviews the evidence for noradrenergic dysfunction in anxiety disorders, derived from indirect measures of noradrenergic function in clinical populations.
引用
收藏
页码:3 / 16
页数:14
相关论文
共 133 条
  • [1] ABELSON JL, 1991, ARCH GEN PSYCHIAT, V48, P157
  • [2] ENDOCRINE, CARDIOVASCULAR, AND BEHAVIORAL-RESPONSES TO CLONIDINE IN PATIENTS WITH PANIC DISORDER
    ABELSON, JL
    GLITZ, D
    CAMERON, OG
    LEE, MA
    BRONZO, M
    CURTIS, GC
    [J]. BIOLOGICAL PSYCHIATRY, 1992, 32 (01) : 18 - 25
  • [3] Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: A preliminary single-blind, 12-week, controlled study
    Albert, U
    Aguglia, E
    Maina, G
    Bogetto, F
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (11) : 1004 - 1009
  • [4] [Anonymous], ANXIETY DISORDERS
  • [5] Antony MM, 1997, AM J PSYCHIAT, V154, P1089
  • [6] Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers
    Argyropoulos, SV
    Bailey, JE
    Hood, SD
    Kendrick, AH
    Rich, AS
    Laszlo, G
    Nash, JR
    Lightman, SL
    Nutt, DJ
    [J]. PSYCHONEUROENDOCRINOLOGY, 2002, 27 (06) : 715 - 729
  • [7] An open clinical trial of reboxetine in the treatment of social phobia
    Atmaca, M
    Tezcan, E
    Kuloglu, M
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) : 417 - 419
  • [8] Bailey JE, 2003, J PSYCHOPHARMACOL, V17, P252, DOI 10.1177/02698811030173002
  • [9] Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
    Baldwin, DS
    Anderson, IM
    Nutt, DJ
    Bandelow, B
    Bond, A
    Davidson, JRT
    den Boer, JA
    Fineberg, NA
    Knapp, M
    Scott, J
    Wittchen, HU
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (06) : 567 - 596
  • [10] Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder
    Bandelow, B
    Sengos, G
    Wedekind, D
    Huether, G
    Pilz, J
    Broocks, A
    Hajak, G
    Ruther, E
    [J]. PHARMACOPSYCHIATRY, 1997, 30 (04) : 113 - 117